CTSD — Cathepsin D

CTSD — Cathepsin D

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CTSD — Cathepsin D</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CTSD</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cathepsin D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1509</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>116840</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000103811</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P07339</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>412 amino acids (preproenzyme)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa (prepro), 31 kDa (mature)</td>
</tr>
<tr>
<td class="label">Enzyme Classification</td>
<td>EC 3.4.23.5 (aspartyl protease)</td>
</tr>
</table>

Overview

CTSD (Cathepsin D) encodes a lysosomal aspartyl endopeptidase that is a central player in protein degradation, autophagy-lysosomal function, and cellular homeostasis in the brain. Cathepsin D is synthesized as a preproenzyme (52 kDa) that undergoes sequential proteolytic processing: signal peptide removal in the ER, removal of the propeptide in the late endosome/lysosome to generate the mature active enzyme composed of a light chain (14 kDa) and heavy chain (31 kDa) heterodimer[@qiu2022].

CTSD — Cathepsin D

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CTSD — Cathepsin D</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CTSD</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cathepsin D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1509</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>116840</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000103811</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P07339</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>412 amino acids (preproenzyme)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa (prepro), 31 kDa (mature)</td>
</tr>
<tr>
<td class="label">Enzyme Classification</td>
<td>EC 3.4.23.5 (aspartyl protease)</td>
</tr>
</table>

Overview

CTSD (Cathepsin D) encodes a lysosomal aspartyl endopeptidase that is a central player in protein degradation, autophagy-lysosomal function, and cellular homeostasis in the brain. Cathepsin D is synthesized as a preproenzyme (52 kDa) that undergoes sequential proteolytic processing: signal peptide removal in the ER, removal of the propeptide in the late endosome/lysosome to generate the mature active enzyme composed of a light chain (14 kDa) and heavy chain (31 kDa) heterodimer[@qiu2022].

Cathepsin D is one of the most abundant lysosomal proteases and is essential for the degradation of long-lived proteins, organelles (mitophagy), and the clearance of pathological protein aggregates. It plays a dual role in neurodegeneration: under normal conditions, it protects neurons by clearing toxic proteins; under pathological conditions, its dysregulation contributes to neuronal death through excessive protease activity, lysosomal membrane permeabilization, and altered processing of disease-relevant substrates[@stoka2021].

Mutations in CTSD cause neuronal ceroid lipofuscinosis type 10 (CLN10), a severe early-onset neurodegenerative storage disorder. Beyond monogenic disease, cathepsin D activity and expression are altered in Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS), making it both a disease biomarker and a therapeutic target[@qiu2022].

Gene and Protein Structure

Protein Architecture

Cathepsin D adopts the classical pepsin-like bilobal structure with two homologous domains:

• N-terminal lobe: Contains the activation peptide (propeptide, ~44 amino acids) that blocks the active site; cleavage of this peptide is required for activation
• C-terminal lobe: Contains the second catalytic aspartate residue
• Active site: Two conserved aspartate residues (Asp33, Asp231 in human enzyme) that coordinate a water molecule for nucleophilic attack on peptide bonds
• Glycosylation: N-linked glycosylation sites (Asn133, Asn271) important for trafficking to lysosomes; mannose-6-phosphate (M6P) tags direct enzyme to lysosomes via M6P receptors
• pH optimum: Strongly acidic (pH 3.5-5.0), optimal for lysosomal environment

Normal Biological Function

Lysosomal Protein Degradation

Cathepsin D is the most abundant lysosomal protease and is responsible for:

• Bulk protein turnover: Degradation of long-lived proteins during normal cellular recycling
• Autophagy substrate clearance: Final degradation step for autophagosome cargo after lysosomal fusion
• Organelle turnover: Mitophagy (mitochondrial degradation), pexophagy (peroxisome), ribophagy (ribosome)
• Protein quality control: Clearing misfolded, aggregated, and damaged proteins

Prohormone and Progrowth Factor Activation

Cathepsin D activates several precursor proteins:

• Proinsulin: Cathepsin D processes proinsulin to active insulin in pancreatic beta cells
• Nerve growth factor (NGF): Pro-NGF is activated by cathepsin D; this is critical for neuronal survival signaling
• Procathepsin D: Auto-activation from zymogen to mature enzyme is a self-contained process

Autophagy Regulation

Cathepsin D influences autophagy at multiple levels:

• Lysosomal fusion: Regulates SNARE machinery for autophagosome-lysosome fusion
• TFEB activation: Cathepsin D activity influences the lysosomal signaling that controls TFEB nuclear translocation
• Aggregate clearance: Directly digests protein aggregates delivered by selective autophagy receptors (p62/SQSTM1, NDP52, optineurin)

Role in Alzheimer's Disease

Amyloid-Beta Metabolism

Cathepsin D has a complex, context-dependent relationship with amyloid-beta ([Aβ](/entities/amyloid-beta)) metabolism[@ambrozak2021]:

Degradative Function (Protective):

• Cathepsin D degrades both Aβ40 and Aβ42 in vitro and in cell models
• Overexpression of cathepsin D reduces extracellular Aβ accumulation in APP transgenic mice
• Cathepsin D knockout mice show impaired Aβ clearance and accelerated plaque formation
• Human AD brain shows increased cathepsin D activity in affected regions, likely reflecting compensatory upregulation

• Cathepsin D can cleave [APP](/entities/app-protein) at certain sites, potentially generating amyloidogenic fragments
• The balance between amyloidogenic and non-amyloidogenic processing depends on cellular context, pH, and co-localization
• In some contexts, cathepsin D may contribute to Aβ production, though this is minor compared to BACE1 and gamma-secretase

Tau Pathology

Cathepsin D is involved in [tau](/proteins/tau) metabolism and pathology[@kumar2022]:

• Cathepsin D cleaves tau at specific sites, generating truncated fragments with different aggregation properties
• Truncated tau fragments generated by cathepsin D can act as seeds for tau aggregation
• Lysosomal dysfunction in AD impairs cathepsin D trafficking and activation, leading to proteostasis failure
• Cathepsin D activity is inversely correlated with tau phosphorylation in some models, suggesting regulatory crosstalk

Lysosomal Dysfunction in AD

AD is increasingly recognized as a lysosomal storage disorder at the cellular level. Features include:

• Endo-lysosomal acidification defects: Vacuolar H+-ATPase dysfunction leads to less acidic lysosomes, impairing cathepsin D activation
• Autophagosome-lysosome fusion deficits: Accumulation of autophagosomes with undigested cargo
• Lysosomal membrane permeabilization (LMP): In advanced disease, lysosomal rupture releases cathepsin D into cytoplasm, triggering apoptotic cascades
• Neuronal lipofuscin accumulation: Age-related accumulation of undegraded material reflects declining cathepsin D function

Neuroinflammation

Cathepsin D in [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes) modulates neuroinflammation[@chen2022]:

• Cathepsin D release from activated microglia contributes to inflammatory signaling
• Cathepsin D cleaves inflammatory mediators and cytokines
• Impaired microglial cathepsin D function leads to defective clearance of cellular debris, perpetuating inflammation
• Cathepsin D in astrocytes affects their metabolic support of neurons

Role in Parkinson's Disease

Alpha-Synuclein Clearance

Cathepsin D is a key enzyme for degrading [alpha-synuclein](/proteins/alpha-synuclein) and clearing alpha-synuclein aggregates[@norenberg2022]:

• Direct degradation: Cathepsin D cleaves alpha-synuclein at multiple sites, reducing fibril formation
• Autophagy flux: Cathepsin D activity is required for autophagic clearance of alpha-synuclein aggregates
• Compensatory upregulation: PD substantia nigra shows increased cathepsin D expression, likely as a compensatory response to rising aggregate burden
• Impaired delivery: Extracellular alpha-synuclein impairs the trafficking of cathepsin D to lysosomes, creating a feedforward cycle of proteostasis failure[@cheng2023]

Relationship to GBA and Lysosomal PD

Heterozygous [GBA](/genes/gba) mutations are the strongest genetic risk factor for PD. Cathepsin D interacts with the GBA pathway:

• GBA deficiency leads to glucosylceramide accumulation, which impairs lysosomal acidification
• Reduced acidification decreases cathepsin D activation
• This creates a double hit: GBA deficiency impairs cathepsin D, which reduces alpha-synuclein clearance, which is already compromised by GBA loss

PD Substantia Nigra Findings

Studies of human PD substantia nigra demonstrate:

• Increased cathepsin D protein and activity in dopaminergic neurons
• Altered processing: more procathepsin D and less mature enzyme, suggesting trafficking defects
• Co-localization of cathepsin D with alpha-synuclein aggregates in Lewy body-containing neurons
• The compensatory increase in cathepsin D may be insufficient to overcome the aggregate burden

Role in Amyotrophic Lateral Sclerosis

TDP-43 Pathology

Cathepsin D is implicated in [TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathy, the hallmark pathology of ALS and frontotemporal dementia[@haim2022]:

• TDP-43 aggregates colocalize with lysosomal markers including cathepsin D in ALS motor neurons
• Cathepsin D can degrade TDP-43 fragments that form aggregates
• Impaired lysosomal function in ALS reduces cathepsin D-mediated TDP-43 clearance
• The autophagy-lysosomal pathway is broadly impaired in ALS due to mutations in genes like C9orf72, TARDBP, and OPTN

Motor Neuron Vulnerability

Motor neurons appear particularly sensitive to cathepsin D dysfunction:

• ALS motor neurons show accumulation of lysosomal storage material and impaired autophagic flux
• Cathepsin D activity is altered in ALS spinal cord
• Enhancing cathepsin D or other lysosomal proteases is being explored as a therapeutic strategy for ALS

ALS Genetics Connection

ALS genes affecting lysosomal function:

• C9orf72: The most common ALS gene; loss of function impairs autophagy-lysosomal pathway
• TBK1: Kinase regulating autophagy receptor phosphorylation and lysosomal function
• OPTN: Autophagy receptor that brings cargo to lysosomes
• SQSTM1 (p62): Autophagy receptor that delivers aggregates for cathepsin D degradation

Neuronal Ceroid Lipofuscinosis Type 10 (CLN10)

Disease Overview

Biallelic mutations in CTSD cause CLN10, one of the most severe forms of neuronal ceroid lipofuscinosis (NCL)[@sunkar2022]:

• Onset: Severe, often congenital or early infantile presentation
• Core features: Progressive neurodegeneration, seizures, visual impairment, developmental regression
• Pathology: Accumulation of ceroid lipofuscin (lysosomal storage material) in neurons and other cell types
• MRI: Rapidly progressive brain atrophy, white matter changes

Molecular Mechanism

The pathogenesis of CTSD-CLN10 reflects the critical role of cathepsin D in lysosomal function:

• Loss of cathepsin D activity leads to accumulation of undegraded substrates in lysosomes
• Ceroid lipofuscin (a complex autofluorescent material from partially degraded lipids and proteins) accumulates
• Lysosomal storage triggers endoplasmic reticulum stress, mitochondrial dysfunction, and ultimately apoptosis
• The early and severe onset reflects the essential nature of cathepsin D in cellular homeostasis

Diagnosis and Management

• Enzyme activity assay: Measure cathepsin D activity in fibroblasts or leukocytes
• Genetic testing: Confirm biallelic CTSD mutations
• Management: Supportive care for seizures, nutritional support, physical therapy; no disease-modifying treatment available

Therapeutic Strategies

Enhancement of Cathepsin D Activity

Several strategies aim to boost cathepsin D function for neurodegenerative disease:

Cathepsin D Inhibitors

While enhancement seems beneficial, some contexts call for inhibition[@liu2023]:

• Cancer: Cathepsin D is overexpressed and secreted by many tumors; inhibitors are being developed as anticancer agents
• Autoimmune disease: Extracellular cathepsin D can activate inflammatory pathways; inhibition might reduce neuroinflammation
• Caution in neurodegeneration: Systemic inhibition would impair lysosomal function and likely worsen disease

Substrate Reduction Approaches

Since cathepsin D degrades both protective and pathogenic substrates, some approaches focus on reducing the pathogenic load:

• BACE1 inhibitors: Reduce Aβ production, relieving the burden on cathepsin D for Aβ clearance
• Alpha-synuclein aggregation inhibitors: Reduce the load of difficult-to-degrade aggregates
• Anti-aggregation compounds: Enhance the solubility of protein aggregates, making them more accessible to cathepsin D

Expression Patterns

Cathepsin D is expressed in most cell types with particularly high levels in:

• Neurons: Especially pyramidal neurons of hippocampus and cortex, cerebellar Purkinje cells
• Microglia: High expression in activated microglia; role in neuroinflammation
• Astrocytes: Important for astrocyte protein turnover and metabolic support
• Liver: Major secretory organ
• Kidney: High lysosomal activity in proximal tubule cells

• Cytoplasmic: Predominantly lysosomal localization
• Neuronal soma: High in cell body; transported to distal compartments
• Synaptic terminals: Present in nerve terminals; degradation of synaptic proteins
• Glial cells: Distributed throughout glial cytoplasm

Molecular Interactions

Substrates

Cathepsin D cleaves a wide range of substrates including:

• APP: Can generate amyloidogenic fragments
• Tau: Generates truncated fragments with variable aggregation properties
• Alpha-synuclein: Degrades monomeric and oligomeric forms; less effective against fibrils
• TDP-43: Cleaves aggregation-prone fragments
• Myelin basic protein: Relevance to demyelinating conditions
• Cytokines and growth factors: Processing/activation role

Protein Interactions

• Cathepsin B: Co-localizes with cathepsin D in lysosomes; often acts together on substrates
• LAMP1/LAMP2: Lysosomal membrane proteins that protect cathepsin D from leakage
• M6P receptor: Directs procathepsin D trafficking to lysosomes
• p62/SQSTM1: Delivers ubiquitinated aggregates to lysosomes for degradation
• GBA: Functional crosstalk through lysosomal pH and lipid environment

Biomarker Potential

Cathepsin D has been investigated as a biomarker for neurodegenerative disease[@kim2021]:

• CSF cathepsin D: Elevated levels in AD and PD compared to controls
• Blood/serum: Less reliable due to contributions from peripheral sources
• Activity-based probes: Chemical probes that label active cathepsin D could track enzyme activity in vivo
• Limitation: Non-specific elevation in many conditions; not disease-specific

Research Models

Cell Culture

• CTSD knockout cells: Complete loss of cathepsin D; severe lysosomal storage phenotype
• CTSD knockdown: Partial reduction; models age-related decline
• Primary neurons: Mouse cortical/hippocampal neurons for studying neuronal cathepsin D function
• iPSC-derived neurons: From patients with CTSD mutations (CLN10) and sporadic disease

Animal Models

• Ctsd knockout mice: Perinatal or early postnatal lethality; severe lysosomal storage; used to understand disease mechanisms
• Ctsd heterozygous mice: Partial deficiency; model age-related decline
• APP/PS1 x Ctsd+/− mice: Cross of AD model with cathepsin D haploinsufficiency; accelerated pathology
• Alpha-synuclein transgenic x Ctsd+/− mice: Show worsened alpha-synuclein pathology with reduced cathepsin D

Chemical/Induced Models

• MPP+ models: Cathepsin D activity altered in dopaminergic cell models
• Rotenone models: Mitochondrial toxins alter lysosomal function and cathepsin D
• Lysosomal storage inducers: Compounds that block lysosomal degradation create models of impaired cathepsin D function

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Cathepsin D in Aβ and tau metabolism
• [Parkinson's Disease](/diseases/parkinsons-disease) — Cathepsin D in alpha-synuclein clearance
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction) — Cathepsin D and lysosomal pathways
• [Autophagy](/mechanisms/autophagy) — Cathepsin D as terminal degradation step
• [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis) — CTSD-CLN10 monogenic disease
• [GBA Gene](/genes/gba) — Lysosomal gene with functional overlap to cathepsin D
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — Cathepsin D in ALS/FTD
• [Neuroinflammation](/mechanisms/neuroinflammation) — Cathepsin D in glial function

External Links

• [NCBI Gene: CTSD](https://www.ncbi.nlm.nih.gov/gene/1509)
• [OMIM: CTSD](https://www.omim.org/entry/116840)
• [UniProt: P07339](https://www.uniprot.org/uniprot/P07339)
• [GeneCards: CTSD](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CTSD)
• [RCSB PDB: Cathepsin D structures](https://www.rcsb.org/pages/search?target=QS&q=cathepsin+D)
• [NCL Resource: CTSD](https://jfchen.ccvisa.net/nclweb/ctsd.html)

References